Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Liver and Pancreas Tumors
•
Internal Medicine
•
Cholangiocarcinoma
•
Inflammatory Bowel Disease
•
Gastroenterology
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
Would you recommend adjuvant Xeloda?
Related Questions
How would you manage a solitary unresectable liver metastasis?
How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?
Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?
In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?
How would you treat an MSI-H metastatic cholangiocarcinoma found on liquid biopsy?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
In patients with active IBD and rectal cancer, do you take any precautions before starting TNT?
What diet do you recommend for patients with inflammatory bowel disease?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?